<DOC>
	<DOCNO>NCT03096184</DOCNO>
	<brief_summary>This non-randomized , phase II , open label study apatinib mesylate tablet plus tegafur gimeracil oteracil potassium capsule recurrent/metastatic squamous cell carcinoma head neck . The primary purpose study evaluate efficacy apatinib mesylate tablet plus tegafur gimeracil oteracil potassium capsule recurrent/metastatic squamous cell carcinoma head neck</brief_summary>
	<brief_title>A Study Apatinib Plus Tegafur Gimeracil Oteracil Recurrent/Metastatic Head Neck Cancers</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>1 . Histologically / cytologically confirm diagnosis recurrent metastatic squamous cell carcinoma head neck origin amenable curative intent therapy ; human papillomavirus ( HPV ) ( + ) HPV ( ) tumor eligible ; tumor ( squamous histology ) unknown primary clearly relate head neck area eligible 2 . Presence measurable lesion ( RECIST V1.1 ) 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 4 . Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L Platelets &gt; = 100 x 10^9/L Hemoglobin ( Hb ) &gt; 9 g/dL Total calcium ( correct serum albumin ) within normal limit Magnesium &gt; = low limit normal institution Potassium within normal limit institution Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within 1.5 x normal range ( = &lt; 3.0 x upper limit normal [ ULN ] liver metastasis present ) Serum bilirubin within normal range ( = &lt; 1.5 x ULN liver metastases present ; total bilirubin = &lt; 3.0 x ULN direct bilirubin within normal range patient well document Gilbert syndrome ) Serum creatinine = &lt; 1.5 x ULN 24hour clearance &gt; = 50 mL/min Serum amylase = &lt; ULN Serum lipase = &lt; ULN Fasting plasma glucose = &lt; 120 mg/dL ( 6.7 mmol/L ) 5 . Negative serum pregnancy test within 72 hour start study treatment woman childbearing potential 6 . Signed informed consent 1 . Patients poorcontrolled arterial hypertension ( systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mm Hg ) despite standard medical management ; 2 . Suffered grade II myocardial ischemia myocardial infarction , uncontrolled arrhythmia ( include QT interval male ≥ 450 m , female ≥ 470 m ) . Grade IIIIV cardiac insufficiency accord New York Heart Association ( NYHA ) criteria echocardiography check : leave ventricular ejection fraction ( LVEF ) &lt; 50 % ; 3 . Patients prior allergic reaction Apatinib ; 4 . The subject another active malignancy within past five year except cervical cancer site , situ carcinoma bladder nonmelanoma carcinoma skin ; 5 . Clinically significant uncontrolled major medical condition include limited : active uncontrolled infection , symptomatic congestive heart failure , Unstable angina pectoris cardiac arrhythmia , psychiatric illness/ social situation would limit compliance study requirement ; medical condition , opinion study investigator place subject unacceptably high risk toxicity ; 6 . Patients undergo therapy investigational agent . 7 . Women pregnant breastfeeding ; 8 . Patients concurrent disease , judgment investigator , would make patient inappropriate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>Apatinib</keyword>
	<keyword>Tegafur Gimeracil Oteracil</keyword>
</DOC>